Key result
Antihypertensive therapy lacks direct evidence of benefit or harm in dementia due to trial exclusions.
Why the study?
Does controlling blood pressure improve or worsen cognitive function and cause adverse effects in people with dementia?
Does controlling blood pressure improve or worsen cognitive function and cause adverse effects in people with dementia?
Due to a lack of direct evidence on treating hypertension in dementia, clinicians should individualize care, use ambulatory monitoring, and consider deprescribing if side effects outweigh benefits.
Clinicians should individualize BP targets in dementia pending evidence; leaves open the need for dedicated RCTs in this excluded population.
The optimal management of hypertension in people with dementia is uncertain. This review explores if people with dementia experience greater adverse effects from antihypertensive medications, if cognitive function is protected or worsened by controlling blood pressure (BP) and if there are subgroups of people with dementia for whom antihypertensive therapy is more likely to be harmful. Robust evidence is scant, trials of antihypertensive medications have generally excluded those with dementia. Observational data show changes in risk association over the life course, with high BP being a risk factor for cognitive decline in mid-life, while low BP is predictive in later life. It is therefore possible that excessive BP lowering in older people with dementia might harm cognition. From the existing literature, there is no direct evidence of benefit or harm from treating hypertension in people with dementia. So what practical steps can the clinician take? Assess capacity, establish patient preferences when making treatment decisions, use ambulatory monitoring to thoroughly assess BP, individualise and consider deprescribing where side effects (e.g. hypotension) outweigh the benefits. Future research might include pragmatic randomised trials of targeted deprescribing, which include patient-centred outcome measures to help support decision-making and studies to address mechanistic uncertainties.
No takes yet. Share an insight, caveat, or question.
Harrison et al. (2016) conducted a review in Hypertension in people with dementia. Antihypertensive medications was evaluated. Antihypertensive therapy in people with dementia lacks direct evidence of benefit or harm, as robust trials have generally excluded this population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: